News

US FDA approves KalVista's oral swelling disorder drug, shares rise
KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug for a type of hereditary swelling disorder, sending its shares up 33.3% in premarket trading.
Clinical Advisor11h
FDA Greenlights Oral Therapy for NSCLC With EGFR Exon20 Insertion Mutations
In a primary efficacy population of 85 patients, the confirmed overall response rate was 46%.
Business Wire16h
KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY® (sebetralstat), a novel ...
Cancer Therapy Advisor22h
Zegfrovy Granted Accelerated Approval for NSCLC With Exon 20 Insertions
The US Food and Drug Administration (FDA) has granted accelerated approval to Zegfrovy (sunvozertinib) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC ...